MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: BioPharmaceuticals _ Biotechnology, Genomics, Genetics, Bioinformatics, Biomanufacturing & Personalized Medicine
2026: The old Vinay Prasad never left. He just changed jobs ... Prasad takes a familiar, conservative approach to drug approvals
uniQure N.V. (NASDAQ:QURE)*
Organization & Developments: UniQure
Iveric bio
Parents
uniQure N.V. (NASDAQ:QURE)*
Children
* Hemophilia
2013: Glybera Gains Official EMA Nod as First Gene Therapy (2013)
2017: Additionally, the FDA has agreed that AMT-061 will be included under the existing Breakthrough Therapy designation for AMT-060
2017: QURE +60% on hemophilia B development updatel • BioPharmCatalyst
2017: uniQure: Continued Upside In 2018 - uniQure N.V. (NASDAQ:QURE)
2017: Will advance its pipeline candidate AMT-061 straight into a pivotal trial in 3Q 2018 for patients with severe and moderately severe hemophilia B.
2018: Uniqure (QURE)_This Biotech Just Rocketed 35% On Its Pfizer-Rivaling Gene Therapy
2018: uniQure Makes Substantial Progress Towards A Large Hemophilia B Market_seekingalpha.com
2019: Encouraging gene therapy data give uniQure an injection of confidence as it preps PhIII showdown with Spark – Endpoints News
2019: This Gene Therapy Stock Is Nearing A Breakout On Its Hemophilia B Study_www.investors.com
2019: uniQure: Targeting Hemophilia B With Gene Therapy_seekingalpha.com
2020: Revisiting UniQure
2020: uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy
2020: UniQure/CSL hit by FDA clinical hold for hem B gene therapy program after liver cancer find
2021: uniQure Should Do Well - Depending On Your Outlook
2021: UniQure: Leading Gene Therapy Company
2022: Biotech Analysis Central Preview Series: uniQure N.V._seekingalpha.com
2022: Bristol Myers has change of heart on cardiovascular gene therapy pact, terminating uniQure deal
2022: FDA approves first gene therapy for hemophilia B
2022: uniQure pauses part of Huntington's trial after 3 patients hospitalized—1 of whom hasn’t fully recovered
2022: uniQure: Hemgenix Approval Key Catalyst To Move The Needle, Rate Buy_ seekingalpha.com
2023: Financials And Pipeline Signal A Promising Outlook For Investors (NASDAQ:QURE)
2023: uniQure offloads 5th of staff, half of R&D projects to keep gene therapies in clinic into 202
2024: uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
2024: UniQure restructuring to claim 300 jobs _ biopharmadive
2024: UniQure shares soar on chance of speedy approval for Huntington’s therapy
2024: uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles
2025: Experimental gene therapy for Huntington’s markedly slowed disease progression in key trial
2025: UniQure (QURE) Stock Jumps 248% on Huntington’s Trial Results. Analysts Raise Price Targets
2025: uniQure Announces FDA Breakthrough Therapy Designation
2025: Uniqure gene therapy for Huntington’s slowed disease progression in key trial
2025: uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data
2025: uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons
2025: uniQure: Price And Value Have Caught Up
2025: uniQure's AMT-130 Gene Therapy Warrants An Upgrade
Jumps
*Key People: Uniqure
Finance & Acquisitions: Uniqure